Clinical Trial: Phase I Study of ANK-101 in Advanced Tumors
Study Status: Completed
Recruit Status: RECRUITING
Condition: Advanced Solid Tumor
Study Type: INTERVENTIONAL
Official Title: A Phase I Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Cutaneous, Subcutaneous, Soft Tissue or Nodal Tumors
Brief Summary:
This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of ANK-101 in participants with advanced solid tumors.
Read more